Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation

Mariah Wright, Hemalatha Rangarajan, Rolla Abu-Arja, Jeffery J. Auletta, Dean Lee, Veronika Polishchuk, Vinita Pai, Kimberly Taylor, Rajinder P.S. Bajwa*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Immunosuppressive prophylaxis is usually given to decrease the development of acute graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Belatacept is a Cytotoxic T-lymphocyte-associated protein 4, blocking agent, an immunosuppressive agent used for organ rejection prevention in adult renal transplant recipients. Methods: We describe two children in whom belatacept was successfully used for GvHD prophylaxis. Case 1 was noncompliant with prior immunosuppressive therapy for aplastic anemia, and Case 2 developed severe thrombotic microangiopathy (TMA) precluding the use of calcineurin inhibitors (CNI) or mTOR inhibitors. Results and Conclusion: Belatacept was found to be a safe alternative in preventing GvHD in 2 patients in whom traditional prophylactic therapies were not possible to use.

Original languageEnglish (US)
Article numbere14041
JournalPediatric transplantation
Volume25
Issue number6
DOIs
StatePublished - Sep 2021

Keywords

  • belatacept
  • graft versus host disease
  • GvHD

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint

Dive into the research topics of 'Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this